Corrigendum to ‘Lack of factor VIII detection in humans and dogs with an intron 22 inversion challenges hypothesis regarding inhibitor risk’(Journal of Thrombosis and Haemostasis, (2024), 22, 12, (3415-3430), (S1538783624004938), 10.1016/j.jtha.2024.08.007)

The authors regret an error in the published paper. One of the monoclonal antibodies used in the study by Vir et al¹, "GMA-8013", was actually the monoclonal antibody GMA-8026, which binds to a different epitope on the factor VIII C2 domain. Both antibodies were purchased from Green Mountain Antibodies, Inc., Burlington, VT, USA, which discovered the labeling error after publication of this paper and notified the authors immediately. Anyone wishing to confirm or repeat experiments described in this paper that reported the use of GMA-8013 should instead use GMA-8026. This labeling error does not affect any of the results or conclusions of this study. The company and the authors would like to apologize for any inconvenience caused by this error. [1]Vir, P. Gunasekera, D. Dorjbal, B. … Lack of factor VIII detection in humans and dogs with an intron 22 inversion challenges hypothesis regarding inhibitor risk J Thromb Haemost. 2024 Dec; 22(12):3415-3430The authors would like to apologise for any inconvenience caused. Vir, P. Gunasekera, D. Dorjbal, B. … Lack of factor VIII detection in humans and dogs with an intron 22 inversion challenges hypothesis regarding inhibitor risk J Thromb Haemost. 2024 Dec; 22(12):3415-3430 The authors would like to apologise for any inconvenience caused.